BioTime, Inc. (NYSEMKT:BTX) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Friday.

Several other brokerages also recently weighed in on BTX. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $6.50 target price (up from $6.00) on shares of BioTime in a research note on Monday, June 19th. Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Finally, ValuEngine raised BioTime from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.33.

BioTime (NYSEMKT BTX) traded up 2.0985% during midday trading on Friday, hitting $2.7975. 59,666 shares of the stock traded hands. The company has a market capitalization of $323.96 million, a price-to-earnings ratio of 4.7017 and a beta of 1.37. BioTime has a 52 week low of $2.47 and a 52 week high of $4.01. The stock’s 50-day moving average price is $2.82 and its 200 day moving average price is $3.09.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/25/biotime-inc-btx-upgraded-by-bidaskclub-to-sell.html.

In other news, Director Broadwood Partners, L.P. purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average cost of $2.60 per share, for a total transaction of $26,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have bought 173,896 shares of company stock valued at $481,840.

Hedge funds have recently modified their holdings of the company. State Street Corp boosted its stake in shares of BioTime by 9.3% in the fourth quarter. State Street Corp now owns 1,045,826 shares of the biotechnology company’s stock valued at $3,775,000 after buying an additional 89,189 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of BioTime by 19.4% in the first quarter. Jane Street Group LLC now owns 92,685 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 15,080 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 939 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of BioTime by 306.7% in the first quarter. Russell Investments Group Ltd. now owns 96,303 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 72,624 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in shares of BioTime during the first quarter valued at about $169,000.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Stock Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related stocks with our FREE daily email newsletter.